SkinBioTherapeutics (LON:SBTX) Announces Quarterly Earnings Results

SkinBioTherapeutics (LON:SBTX) issued its quarterly earnings results on Wednesday. The company reported GBX (0.46) (($0.01)) EPS for the quarter, Digital Look Earnings reports. SkinBioTherapeutics had a negative net margin of 237.95% and a negative return on equity of 115.86%.

SkinBioTherapeutics Trading Down 0.4 %

LON:SBTX traded down GBX 0.10 ($0.00) during trading hours on Friday, reaching GBX 24 ($0.31). The company’s stock had a trading volume of 575,179 shares, compared to its average volume of 817,032. The company has a debt-to-equity ratio of 27.57, a quick ratio of 10.01 and a current ratio of 0.93. The firm has a market capitalization of £54.82 million, a price-to-earnings ratio of -14.76 and a beta of 2.01. The firm has a 50-day simple moving average of GBX 20.16 and a 200-day simple moving average of GBX 16.70. SkinBioTherapeutics has a 1 year low of GBX 8.32 ($0.11) and a 1 year high of GBX 26.45 ($0.34).

About SkinBioTherapeutics

SkinBioTherapeutics plc, a life science company, engages in identification and development of technology that harnesses the human microbiome to improve health in the United Kingdom, the United States, and Europe. It develops SkinBiotix technology that promotes skin health by harnessing the beneficial properties of probiotic bacteria and the active components; and AxisBiotix technology that focuses on the gut-skin relationship and is designed to alleviate the symptoms associated with psoriasis.